nference Establishes AI Initiative with Takeda to Advance Precision Medicine in Inflammatory Bowel Disease
17 Julio 2024 - 7:15AM
Business Wire
Collaboration aims to identify personalized
treatment approaches and improve care for patients with IBD
nference today announced a strategic research alliance with
Takeda aimed at harnessing artificial intelligence (AI) to optimize
patient care in inflammatory bowel disease (IBD), a chronic
gastrointestinal disorder affecting millions globally.
The collaboration, known as Project SUCCINCT (Systematic
UC & Crohn’s INformatics Clinical
Toolkit), will utilize nference’s advanced machine learning
models to analyze de-identified electronic health records. By
harnessing AI to identify patients who could benefit from advanced
medical interventions, the initiative aims to personalize treatment
options and improve care for those living with IBD.
“Takeda is at the forefront of gastroenterology, especially in
the area of IBD, and we are honored to collaborate with them on
this critical research,” said Maulik Nanavaty, President of
Ventures at nference & CEO at Anumana. “Project SUCCINCT seeks
to fill a void by more effectively managing treatment of patients
early in their IBD journey, which persists as an area of
significant unmet medical need due to its intricate and diverse
nature. This initiative will leverage our state-of-the-art,
AI-enabled platform to unlock previously undiscovered insights and
information that will help facilitate more precise and targeted
interventions with the disease.”
“AI-driven innovation represents a promising new frontier in
medicine. We’re pleased to join forces with nference on this vital
research endeavor seeking to improve the diagnostic and treatment
journey for patients around the world living with IBD,” said Vijay
Yajnik, MD, PhD, Vice President, Head of U.S. Medical in
Gastroenterology at Takeda, a biopharmaceutical leader
headquartered in Japan with a global hub in Cambridge, Mass. “By
harnessing AI, we can push beyond the boundaries of what is
possible today to empower healthcare providers with information to
help tailor treatment selection for patients, precisely when
needed.”
nference's federated AI platform, nSights, introduced in 2021,
provides researchers with access to insights from a curated,
de-identified dataset spanning all therapeutic areas, including
gastroenterology, cardiology, oncology, metabolic diseases,
immunology, and infectious diseases.
About nference
nference is unlocking the potential of healthcare data with AI,
delivering real-world evidence, insights, and solutions informed by
the most comprehensive multimodal data across all therapeutic
areas. Our extensive de-identified, longitudinal data includes
decades of clinical notes along with rich patient histories,
vitals, lab tests, radiology images, digital pathology, genomics,
and electrophysiology waveforms. Our federated data platform,
comprised of premier healthcare organizations, including Mayo
Clinic, Duke Health, Banner Health, Vanderbilt University Medical
Center, and Emory Healthcare, enables advanced research and custom
AI model development. With unprecedented access to data from over
40 million patient journeys, our partners can accelerate target
discovery, optimize clinical trial design, and enhance lifecycle
management. Follow nference on LinkedIn. Visit us at
www.nference.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240717546296/en/
Andrea Sampson President/CEO, Sampson Public Relations Group
asampson@sampsonprgroup.com